Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results

Patrick Y. Wen; Melissa Lynne Johnson; Jason Timothy Henry; Alex Spira; James Battiste; Iyad Alnahhas; Do Hyun Nam; Jyoti D. Patel; William Jeffery Edenfield; Adilia Hormigo; Shinkyo Yoon; Tae Min Kim; Sudharshan Eathiraj; Julio Hajdenberg; Sergey Yurasov; Manmeet Singh Ahluwalia

doi:10.1200/JCO.2024.42.16_suppl.2068

Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results

Patrick Y. Wen
, Melissa Lynne Johnson
, Jason Timothy Henry
, Alex Spira
, James Battiste
, Iyad Alnahhas
, Do Hyun Nam
, Jyoti D. Patel
, William Jeffery Edenfield
, Adilia Hormigo
, Shinkyo Yoon
, Tae Min Kim
, Sudharshan Eathiraj
, Julio Hajdenberg
, Sergey Yurasov
, Manmeet Singh Ahluwalia

Baptist Health South Florida

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	2068
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	42
Issue number	16
DOIs	https://doi.org/10.1200/JCO.2024.42.16_suppl.2068
State	Published - 2024

ASJC Scopus Subject Areas

Oncology
Cancer Research

Access to Document

10.1200/JCO.2024.42.16_suppl.2068

Cite this

Wen, P. Y., Johnson, M. L., Henry, J. T., Spira, A., Battiste, J., Alnahhas, I., Nam, D. H., Patel, J. D., Edenfield, W. J., Hormigo, A., Yoon, S., Kim, T. M., Eathiraj, S., Hajdenberg, J., Yurasov, S., & Ahluwalia, M. S. (2024). Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results. Journal of Clinical Oncology, 42(16), 2068. https://doi.org/10.1200/JCO.2024.42.16_suppl.2068

Wen, PY, Johnson, ML, Henry, JT, Spira, A, Battiste, J, Alnahhas, I, Nam, DH, Patel, JD, Edenfield, WJ, Hormigo, A, Yoon, S, Kim, TM, Eathiraj, S, Hajdenberg, J, Yurasov, S & Ahluwalia, MS 2024, 'Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results', Journal of Clinical Oncology, vol. 42, no. 16, pp. 2068. https://doi.org/10.1200/JCO.2024.42.16_suppl.2068

@article{6b341a51d95c4d7c9eb7bcade95747ce,

title = "Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results",

author = "Wen, \{Patrick Y.\} and Johnson, \{Melissa Lynne\} and Henry, \{Jason Timothy\} and Alex Spira and James Battiste and Iyad Alnahhas and Nam, \{Do Hyun\} and Patel, \{Jyoti D.\} and Edenfield, \{William Jeffery\} and Adilia Hormigo and Shinkyo Yoon and Kim, \{Tae Min\} and Sudharshan Eathiraj and Julio Hajdenberg and Sergey Yurasov and Ahluwalia, \{Manmeet Singh\}",

year = "2024",

doi = "10.1200/JCO.2024.42.16\_suppl.2068",

language = "English",

volume = "42",

pages = "2068",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

number = "16",

}

TY - JOUR

T1 - Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma

T2 - Preliminary dose escalation results

AU - Wen, Patrick Y.

AU - Johnson, Melissa Lynne

AU - Henry, Jason Timothy

AU - Spira, Alex

AU - Battiste, James

AU - Alnahhas, Iyad

AU - Nam, Do Hyun

AU - Patel, Jyoti D.

AU - Edenfield, William Jeffery

AU - Hormigo, Adilia

AU - Yoon, Shinkyo

AU - Kim, Tae Min

AU - Eathiraj, Sudharshan

AU - Hajdenberg, Julio

AU - Yurasov, Sergey

AU - Ahluwalia, Manmeet Singh

PY - 2024

Y1 - 2024

UR - https://www.scopus.com/pages/publications/105023519516

UR - https://www.scopus.com/pages/publications/105023519516#tab=citedBy

U2 - 10.1200/JCO.2024.42.16_suppl.2068

DO - 10.1200/JCO.2024.42.16_suppl.2068

M3 - Article

AN - SCOPUS:105023519516

SN - 0732-183X

VL - 42

SP - 2068

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this